Marico raises stake in Plix parent to 84.09%; Q2 revenue expected to grow in double digits

What happened: Marico said it entered definitive agreements to acquire 38.18% of Satiya Nutraceuticals in tranches. It completed a 24.09% tranche on October 5, 2026, raising its holding from 60% to 84.09% on a fully diluted basis. Key numbers: Current tranche consideration Rs 1,012.03 crore. Aggregate consideration for 84.09% at Rs 1,392.07 crore. Why it matters: Marico expects consolidated revenue to grow in double digits and operating profit in the mid-twenties, and said it is likely to surpass near-term guidance across key financial parameters.

Marico said it entered definitive agreements to acquire 38.18% of Satiya Nutraceuticals in tranches. It completed a 24.09% tranche on October 5, 2026, raising its holding from 60% to 84.09% on a fully diluted basis.

Marico expects consolidated revenue to grow in double digits and operating profit in the mid-twenties, and said it is likely to surpass near-term guidance across key financial parameters.